Feed Articles Analyses
Analyses BLACK

She designs drugs with AI, and Cathie Wood wanted her at $16. Today it's $14

An AI-designed cancer drug reached patients in two years. Its maker raised $172 million on the stock market, and funds linked to Cathie Wood and Druckenmiller wanted shares. Then the price fell 62% in three weeks.

Key points

  • An AI-designed cancer drug reached patients in two years instead of the usual four.

  • Cathie Wood's and Stanley Druckenmiller's funds wanted $60 million worth of shares, while the market sent them down 62%.

  • The company collected roughly $100 million from partners, but just $24 million appeared in its revenue statement.

  • After subtracting cash, the market values three drugs in clinical trials and eight partnerships at just $240 million.

  • April 12, 2027 is the date that could unlock nearly 38 million shares that are currently restricted.

The smartest money on one side, the screen on the other

Imagine a cancer drug designed not by a team of chemists at a lab bench, but by a computer model - and reaching its first patients in about two years, roughly half the usual time. That's exactly what Iambic Therapeutics $IAM has in hand, a San Diego company whose shares have traded on the Nasdaq since October 15, 2026.

The list of backers sounds like an invitation to the best party in Silicon Valley. Nvidia is among its shareholders. Cathie Wood's funds and billionaire Stanley Druckenmiller signaled before the offering that they wanted to buy up to $60 million worth of shares. Pharmaceutical giant AbbVie signed a multiyear agreement with the company in September. And four major investment banks underwriting the offering assigned it price targets of $22 to $35 in November.

The market sees it differently. The stock went public at $16, climbed to $25 the next day, and then began a slide that took it to $9.60 on November 6. When the company published its first quarterly results on November 16, the price fell another 9.5%. And the very next day it jumped 20% to $14.22.

A ride like that in five weeks usually means something fundamental has happened at the company. Here, nothing did: the drugs in development, the partners, and the cash are all the same as on the day of the offering. What changed was simply who was selling the stock and how many shares were available on the market.

One number is missing from the headlines. Subtract the cash on the company's accounts from its total market value, and you get the amount the market assigns to the AI lab, three drugs in clinical testing, and eight partnerships combined. And that amount is lower than anyone who has read only the price targets would expect.

Bulios Black

Finish the whole article on IAM

And you also unlock fair value and more tools

IA
IAM Bulios Fair Price
By how much? Unlock
UndervaluedFairOvervalued

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Black membership: analyses, screener, newsletters and unlimited StockBot.

4.45 · +200K investors in the community

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy